PTN earnings: next report 2026-09-02, real EPS beat/miss history, analyst consensus Buy, P/E -1.75. Updated 2026-07-23.
Palatin Technologies (PTN) Research Hub
Palatin Technologies (PTN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 11.8 USD (-4.30%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.75, market cap 0.01B. This hub links to the full technical, earnings and options research available for PTN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 11.8 USD (-4.30%) |
| 52-week range | 7.21 USD – 14.01 USD |
| Trend regime | Range |
| 14-day RSI | 74 (Overbought) |
| Trailing P/E | -1.75 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-02 |
Available research for PTN
Covered Call on PTN: how it works, illustrative setup around the real 11.8 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on PTN: how it works, illustrative setup around the real 11.8 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on PTN: how it works, illustrative setup around the real 11.8 USD price, max profit/loss, breakeven and when to use it. Educational.
PTN technical analysis: range, last 11.8 USD, RSI 74, 52w range 7.21 USD–14.01 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is PTN in?
Palatin Technologies (PTN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is PTN in an uptrend or downtrend?
As of 2026-09-11, PTN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is PTN's trailing P/E ratio?
PTN's trailing P/E is -1.75, with a market cap of 0.01B. See the earnings research page for full valuation detail.
When does PTN next report earnings?
PTN is next scheduled to report earnings on 2026-09-02, with a consensus EPS estimate of -1.2 USD.